Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amgen (AMGN) PT Raised to $195 at Argus on 2Q Report; 'Contributors to Top-Line Growth: Kyprolis, Prolia & Sensipar'
July 27, 2017 10:11 AM EDTArgus raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Buy rating, following the company's second quarter earnings report.
Analyst David Toung notes the company delivered second quarter earnings per share and revenue results above consensus projections fueled by several... More
Amgen (AMGN) PT Raised to $180 at UBS Following Solid 2Q
July 26, 2017 8:34 AM EDTUBS raised its price target on Amgen (NASDAQ: AMGN) to $180.00 (from $175.00) while maintaining a Neutral rating. 2Q results were better than expectations with a $145M top-line beat. EPS also beat consensus estimates by $0.18.
UBS increased 2017 Enbrel sales estimates to $5.38B from $5B... More
Amgen (AMGN) PT Raised to $174 at Deutsche Bank
July 26, 2017 6:18 AM EDTDeutsche Bank raised its price target on Amgen (NASDAQ: AMGN) to $174.00 (from $172.00) while maintaining a Hold rating.
Analyst Andrew Peters called the quarter "solid" but said the near term outlook remains challenged.
"While the results beat expectations, we remain cautious on... More
